BRIEF published on 12/12/2024 at 21:35, 8 days 21 hours ago Medincell Joins Euronext SBF 120 Index Market Capitalization Medincell CAC 40 Euronext SBF 120 Financial Visibility
PRESS RELEASE published on 12/12/2024 at 21:30, 8 days 21 hours ago Inside Information / Other news releases Medincell joins Euronext SBF 120 & CAC Mid 60 indices, enhancing visibility and investor appeal. Market capitalization-based indices by Euronext. Effective inclusion from Dec 20 Market Capitalization Medincell Index Inclusion Euronext SBF 120 CAC Mid 60
BRIEF published on 11/28/2024 at 18:45, 23 days ago Medincell Announces Video Conference for Half-Year Results Half-year Results Schizophrenia Medincell Videoconference BEPO Technology
BRIEF published on 11/22/2024 at 18:05, 29 days 1 hour ago MedinCell: Update of share capital and voting rights Share Capital Voting Rights Euronext Actions Medincell
BRIEF published on 11/06/2024 at 13:47, 1 month 15 days ago Medincell: 2024 revenues on the rise and significant clinical progress Clinical Trial Revenue Projections Medincell Olanzapine LAI UZEDY
PRESS RELEASE published on 11/06/2024 at 13:42, 1 month 15 days ago Inside Information / Other news releases Medincell achieves 25% increase in 2024 UZEDY® revenue outlook reaching $100M and key milestone in Olanzapine LAI Phase 3 clinical trials. Teva Pharmaceuticals shares Q3 results Revenue Clinical Trials Medincell Teva Pharmaceuticals UZEDY
BRIEF published on 10/01/2024 at 15:47, 2 months 20 days ago Threshold crossing by Mirova in MEDINCELL Capital Actions Threshold Crossing Medincell Mirova
BRIEF published on 09/24/2024 at 11:54, 2 months 27 days ago Teva and Medincell Present Promising Results on Olanzapine LAI for Schizophrenia Clinical Trial Schizophrenia Medincell Teva Olanzapine LAI
PRESS RELEASE published on 09/24/2024 at 11:53, 2 months 27 days ago Inside Information / Other news releases Teva and Medincell reveal positive efficacy, safety, and tolerability data from Phase 3 study on Olanzapine LAI for schizophrenia treatment, presenting at ECNP 2024 Schizophrenia Treatment Phase 3 Study Medincell Teva Olanzapine LAI
BRIEF published on 09/18/2024 at 10:13, 3 months 3 days ago Mirova crosses the threshold of 5% of voting rights in MEDINCELL Voting Rights Actions Threshold Crossing Medincell Mirova
Published on 12/21/2024 at 01:30, 17 hours 43 minutes ago Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 17 hours 43 minutes ago iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 19 hours 8 minutes ago Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/20/2024 at 23:30, 19 hours 43 minutes ago Boron One Announces Extension to Early Warrant Exercise Incentive Program
Published on 12/21/2024 at 00:51, 18 hours 21 minutes ago Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 18 hours 27 minutes ago EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 18:00, 1 day 1 hour ago ARYZTA AG Announces New Board Technology Committee
Published on 12/21/2024 at 12:17, 6 hours 55 minutes ago AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 1 day 1 hour ago Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 1 day 1 hour ago Disclosure of trading in own shares from 16/12/2024 to 20/12/2024
Published on 12/20/2024 at 14:00, 1 day 5 hours ago Safran: Woodward Signs Agreement to Acquire Safran’ s Electromechanical Actuation Business based in North America
Published on 12/19/2024 at 18:30, 2 days ago Share capital decrease by way of treasury shares cancellation
